Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Matthias Ilmer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9597-1368; OpenAlex author ID A5054969006. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
72
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 4 papers · 2026: 1 paper

Papers 19

  1. The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Co-author DOI 10.1155/mi/2632235↗
  2. Prognostic value of tumor-infiltrating lymphocytes, tumor associated neutrophils and metabolic checkpoint molecules on survival of patients with metastatic pan… Co-author DOI 10.1016/j.sipas.2025.100320↗
  3. Microbiome Dysbiosis With Enterococcus Presence in the Upper Gastrointestinal Tract Is a Risk Factor for Mortality in Patients Undergoing Surgery for Pancreati… Last author DOI 10.1097/sla.0000000000006210↗
  4. Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC. Last author DOI 10.1186/s12893-024-02647-1↗
  5. Smad2 Cooperating with TGIF2 Contributes to EMT and Cancer Stem Cells Properties in Pancreatic Cancer via Co-Targeting SOX2. Co-author DOI 10.7150/ijbs.102381↗
  6. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture. Co-author DOI 10.1007/s00432-023-05100-7↗
  7. WNT enhancing signals in pancreatic cancer are transmitted by LGR6. Last author DOI 10.18632/aging.205101↗
  8. Calreticulin promotes EMT in pancreatic cancer by enhancing endoplasmic reticulum stress-induced autophagy Co-author DOI 10.21203/rs.3.rs-1963841/v1↗
  9. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  10. Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matche… Co-author DOI 10.1186/s12893-021-01083-9↗
  11. Identification of the Neurokinin-1 Receptor as Targetable Stratification Factor for Drug Repurposing in Pancreatic Cancer. Last author DOI 10.3390/cancers13112703↗
  12. [Surgery for isolated local recurrence and metachronous oligometastasis in pancreatic cancer]. Co-author DOI 10.1007/s00104-020-01190-y↗
  13. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  14. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Co-author DOI 10.1016/j.suronc.2019.08.010↗
  15. Repurposed Drugs in Pancreatic Ductal Adenocarcinoma: An Update. Co-author DOI 10.1097/ppo.0000000000000372↗
  16. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  17. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs). Last author DOI 10.3390/medsci5020014↗
  18. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident st… First author DOI 10.18632/oncotarget.7066↗
  19. RSPO2 Enhances Canonical Wnt Signaling to Confer Stemness-Associated Traits to Susceptible Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-14-1327↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bernhard Willibald Renz · 14 shared papers, 2017–2026 · strength 2.22
  2. Jens Werner · 14 shared papers, 2017–2026 · strength 2.08
  3. Jan Goesta D’Haese · 12 shared papers, 2017–2026 · strength 1.82
  4. Hanno Nieß · 6 shared papers, 2019–2025 · strength 0.86
  5. Maximilian Weniger · 4 shared papers, 2019–2026 · strength 0.72
  6. Alexandr V. Bazhin · 4 shared papers, 2021–2025 · strength 0.66
  7. Rainer Christoph Miksch · 3 shared papers, 2021–2026 · strength 0.64
  8. Iris Beirith · 4 shared papers, 2021–2025 · strength 0.63
  9. Steffen Ormanns · 3 shared papers, 2020–2025 · strength 0.52
  10. Christoph Benedikt Westphalen · 5 shared papers, 2017–2023 · strength 0.49
  11. Tengis Tschaidse · 2 shared papers, 2025 · strength 0.42
  12. Weiwei Sheng · 2 shared papers, 2022–2025 · strength 0.38
  13. Yang Feng Wu · 1 shared paper, 2026 · strength 0.29
  14. Qi Li · 1 shared paper, 2026 · strength 0.29
  15. Tao Zhang · 1 shared paper, 2025 · strength 0.23
  16. Fuqiang Zu · 1 shared paper, 2025 · strength 0.23
  17. Ughur Aghamaliyev · 1 shared paper, 2025 · strength 0.23
  18. Guopei Luo · 1 shared paper, 2025 · strength 0.23
  19. Heinz Johannes Buhr · 1 shared paper, 2025 · strength 0.22
  20. Tobias Keck · 1 shared paper, 2025 · strength 0.22
  21. Michael B. Ghadimi · 1 shared paper, 2025 · strength 0.22
  22. Soeren Torge Mees · 1 shared paper, 2025 · strength 0.22
  23. Waldemar H. Uhl · 1 shared paper, 2025 · strength 0.22
  24. Christoph Reißfelder · 1 shared paper, 2025 · strength 0.22
  25. Juliana de Castilhos · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.